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The diagnosis of oral lichen planus (OLP) is based on clinical examination and histopathological criteria. Noninvasive diagnostics
of saliva may be considered as a confirmation of OLP diagnosis and a potential alternative to an invasive method. The objective of
the present study was to evaluate the relationship between the level of tyrosine (Tyr) as well as antioxidants like uric acid (UA) and
glutathione peroxidase (GPx) activity in the saliva of patients with OLP in comparison with the control group (healthy subjects
without any oral changes). A total of 40 patients with OLP and 40 healthy volunteers were selected for the study based on the
modified WHO diagnostic (clinical and histopathological) criteria. High-performance liquid chromatography (HPLC) was
performed for Tyr concentration, while GPx activity and uric acid levels were determined by a colorimetric method. The
concentrations of Tyr, UA, and GPx activity were statistically lowered in OLP patients compared to the control group. All
examined parameters correlated strongly and positively with each other. Mean values of salivary UA concentrations differed
between the groups of OLP patients (reticular and erosive forms) and controls (206.66 vs. 196.54 vs. 218.49μmol/L, respectively,
p = 0:001). A similar trend was demonstrated in salivary Tyr concentration which differed statistically between the study and
control groups (0.08 vs. 0.07 vs. 0.13 μmol/L, respectively, p = 0:001). Determining of a relationship between the concentrations
of Tyr, UA, and GPx activity may be useful in the prognosis of OLP. The HPLC method may be employed, as an additional
noninvasive diagnostic procedure to screen OLP patients, during the routine diagnostics of salivary biochemical parameters
such as aromatic amino acids.
1. Introduction
One of the most commonly encountered lesions of the oral
mucosa is oral lichen planus (OLP) which affects 0.1–4% of
the adult population. It is a chronic inflammatory disease of
the oral mucosa of unknown etiology. OLP is considered a
potentially malignant disorder with an approximately 1%
risk of developing oral squamous carcinoma [1]. Several
clinical presentations of OLP are recognized, with the most
common being reticular and erosive types. The reticular form
presents as fine white lines (known asWickham’s striae) with
an erythematous border. The striae are usually asymptomatic
and located symmetrically on the buccal mucosa, on the ton-
gue and gums. In contrast, erosive OLP is predominantly
associated with pain and oral discomfort and presents as a
mixture of ulcerated and erythematous areas, surrounded
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by striae. Typically, one patient may have a different presen-
tation of OLP transforming from one pattern to another over
time with unknown reason [2]. Interestingly, there is a signif-
icantly higher risk of malignant transformation in the course
of erosive OLP in comparison with its reticular form (33% vs.
13%, respectively), and hitherto, an invasive biopsy remains
the gold standard for diagnosis as well as monitoring of
OLP and other potentially malignant disorders [3]. Hence,
researchers have tried to investigate alternative, noninvasive
methods of monitoring potentially malignant oral disorders.
It has been suggested that in OLP, oxidative stress can
initiate local tissue damage [4] and modify the clinical form
of the disease. This stems from the fact that many transcrip-
tion factors are related to the induction of oxidative stress in
OLP, including Nrf2, NF-κB, Notch, p-53, and AP-1. Their
contribution translates into the regulation of the expression
of genes encoding compounds responsible for detoxification
of free radicals (enzymatic and nonenzymatic antioxidants),
restoration of oxidative-antioxidative balance by these com-
pounds, and control of further cell functions, such as prolif-
eration or apoptosis [5]. The extent to which these changes
will occur and their further impact on clinical manifestations
of OLP (reticular or erosive type) depends on the local level
of salivary antioxidants (antioxidants that can defend against
oxidative stress) [6]. Antioxidative enzymes present in mam-
malian cells, such as superoxide dismutase (SOD), catalase
(CAT), or glutathione peroxidase (GPx), as well as nonenzy-
matic antioxidative systems which include, among others,
urinary acid (UA) or vitamins A and E [7] may significantly
affect these processes. The results of many studies indicate
that UA plays an important role in the removal of free oxy-
gen radicals as the dominant nonenzymatic antioxidant in
the body [8]. Its salivary level has been proven to be closely
related to blood content [9].
A number of studies have appraised the importance of
monitoring oxidative stress parameters in the saliva of OLP
patients [10–13]. Their results indicating a decline in the ele-
ments of antioxidative defense (decrease in levels of GSH,
FRAP, CAT, and SOD) and intensification of oxidative stress
(increase in levels of malonyldialdehyde or 8-hydroxy-2′
-deoxyguanosine) compared to the healthy individuals con-
firm escalation of oxidative/nitrosative stress in patients with
OLP [11, 14–16]. In our previous report, we demonstrated
that the values of antioxidant potential and reduced glutathi-
one are approximately 21% lower in the reticular form ofOLP
and by approximately 40% in its erosive type as compared to
controls [11]. Likewise, we found TBARS determinations to
be significantly different between both forms of OLP [11].
However, no further data are available to explain the observed
changes with respect to the clinical OLP phenotype.
It has been proposed that the level of salivary tyrosine,
classified in a group of aromatic amino acids (AAA), may
be used to discriminate clinical manifestations of OLP.
In vivo, tyrosine (Tyr), and more specifically its derivative,
e.g., 3-nitrotyrosine (3-NT), undergoes free radical modifica-
tions, making it a promising biomarker for the intensification
of oxidative/nitrosative stress (Figure 1) [17–19]. With
regard to ongoing free radical stress observed through
apparent decrease in the key antioxidant enzymes (GPx,SOD,
and CAT), Tyr nitration can block the mechanism associated
with their recompensation (restoring their original antioxi-
dant functions). Hence, some antioxidant enzymes (includ-
ing manganese superoxide dismutase, MnSOD) under
conditions of increased oxidative/nitrosative stress temporar-
ily lose their original functions (associated with defense
against free radicals) and, for the time being, become inactive
forms of enzymes. This contributes to the generation or exac-
erbation of already existing oxidative stress [20]. The molec-
ular mechanism of the observed changes relates to changes
in the activity of intracellular signaling pathways mediated
by, among others, tyrosine kinases, i.e., MAPK and PI3K or
transcription factors (i.e., Nrf2, AP-1, NF-κB, and p53),
maintaining normal functions of proteins involved in the
preservation redox balance in cells, i.e., enzymes producing
reactive oxygen and nitrogen species (RONS) and system
component antioxidants [21]. These disturbances may
cause further pathological changes, resulting in apoptosis
of keratinocytes or their degeneration, which is more fre-
quently observed in the erosive form of OLP (more prone
to malignancy) than in its reticular counterpart. Interest-
ingly, abnormalities in Tyr levels may change the clinical
phenotype of the disease as a result of damage to the
extracellular matrix in OLP [22], which would explain the
somewhat subjective changes in clinical signs and symptoms
of OLP.
Monitoring of salivary levels of antioxidant system
parameters is a noninvasive alternative to surgical interven-
tion, i.e., taking a biopsy for histopathological examination.
Previously published studies have focused on the determina-
tion of oxidative stress in the general group of patients with
OLP, regardless of the clinical phenotype of the disease. In
the current study, we attempted to determine potential
markers which enable assessing the level of salivary antioxi-
dative defense and verifying any oxidative-antioxidant
imbalance associated with the clinical phenotype of OLP.
Hence, the aim of the current study is to assess the useful-
ness of salivary amino acid determination in discrimination
of Tyr levels between patients with OLP and healthy individ-
uals and to determine its relationship with salivary antioxida-
tive defense indicators represented by GPx and UA, with the
intention of establishing a distinction between reticular and
erosive OLP forms.
2. Materials and Methods
2.1. Patient Recruitment. The study was performed in the
Department of Periodontology and Oral Medicine, Institute
of Dentistry, Jagiellonian University Medical College,
Krakow, Poland. The recruitment of patients was carried
out between May 2016 and December 2018. The number of
study participants totaled 40. All participants gave written,
informed consent. The study protocol was approved by the
Bioethics Committee of the Jagiellonian University in
Krakow, Poland (No. KBET/112/b/2014). The study was per-
formed in accordance with the Helsinki Declaration of 2008.
The criterion for inclusion was the clinical diagnosis of
reticular or erosive form of OLP. Pregnant women,
patients treated for systemic or local diseases, patients
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supplemented with antioxidants (vitamins, preparations con-
taining antioxidants, i.e., ointments and extracts) within the
last three weeks, patients with any inflammatory lesions of
the oral mucosa, patients with history of oral malignancy,
patients chewing gum, and those treated for OLP in the last
3 months were excluded from the study.
Clinical diagnosis of reticular OLP was made in the cases
of asymptomatic oral lesions presenting with white lacy lines
surrounded by an erythematous border. Twenty-six patients
with reticular OLP were recruited to the study group. The
lesions were located mainly on the buccal mucosa and less
frequently on the tongue or the gums.
In turn, clinical diagnosis of erosive OLP was made in the
cases of symptomatic oral lesions presenting with erosions or
ulcerations within erythematous changes surrounded by
white lacy lines. Fourteen patients with erosive OLP were
recruited to the study group. Erosive OLP lesions were
mainly located on the buccal mucosa, edges of the tongue,
or simultaneously in both sites.
The tentative clinical diagnosis of reticular or erosive
OLP was made by a dentist with experience in oral medicine.
The clinical diagnosis was subsequently confirmed by a his-
topathological examination as per the modified WHO diag-
nostic criteria [23].
Forty healthy individuals without any lesions of the oral
mucosa were recruited to the control group.
2.2. Collection and Preparation of Saliva. Patients were asked
to avoid eating meals and consuming any liquids 2 hours
before the examination. Before the saliva collection, patients
rinsed their mouth thoroughly with a minimum of 10mL
of deionized water. They sat comfortably with their eyes open
and their head slightly tilted forward to facilitate the collec-
tion of saliva from the floor of the mouth. Saliva samples
were collected between 9 and 11 AM with the subjects
chewing a cotton swab devoid of any saliva-stimulating agent
(to avoid interference) for 5min. The swab was then placed
in a sterile plastic centrifuge tube provided by the manufac-
turer (Salivette Sarstedt Germany System). The samples were
stored at 4°C and transported on ice. Material preparation for
the examination started no later than 2 hours after sampling.
The saliva samples were centrifuged for 10min at 900 rpm at
4°C, and the resulting filtrate was transferred to sterile 1.5mL
microtubes, which were then centrifuged at 10,000 rpm at
4°C for 10 minutes to remove debris (insoluble components,
cells, and impurities). A part of the saliva was transferred to
1.5mL microtubes with the addition of 15μL of 0.15M solu-
tion of butylated hydroxytoluene in ethanol per 1mL of
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Figure 1: The role of aromatic amino acids (AAA) in the organism and induction of tyrosine derivatives (3,4-dihydroxyphenylalanine
(DOPA) and 2,5-dityrosine) by reactive oxygen species. Phenylalanine (Phe) is converted to tyrosine (Tyr) in the liver and kidneys with
the participation of phenylalanine hydroxylase (PAH). Tyr is used for the synthesis of catecholamines (dopamine, epinephrine, and
norepinephrine) in the adrenal medulla and for the synthesis of pheo- and eumelanins in skin melanocytes, the first stage of which is the
formation of L-DOPA. An elevated L-DOPA/L-Tyr ratio occurs in patients with malignant melanoma and local lymph node metastases.
Tyr is also the starting compound for the synthesis of thyroid hormones—thyroxine (T4) and tri-iodothyronine (T3). In addition, Tyr
derivatives such as 3-Cl-D-Tyr or 3-N-D-Tyr may be formed under oxidative, nitrifying, and chlorinating stress conditions. Tyr catalyzes
the reaction that converts Trp to kynurenine (KYN). IDO (indoleamine-2,3-dioxygenase) and TDO (tryptophan-2,3-dioxygenase) are
induction enzymes that are activated under stressful situations, among others under the proinflammatory cytokines.
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saliva, in order to prevent lipid peroxidation during storage
of the samples. A part of the saliva was deproteinized using
trichloroacetic acid, 30μL of which was added to 90μL of
the material, vortexed, and centrifuged for 5min at
12,000 rpm. The supernatant was transferred to a separate
tube placed on ice. The acidic clear solution was stored at
-80°C until HPLC analysis (no more than 2 months).
2.3. Determination of Tyrosine. All chemical solvents and
standards were of analytical grade. Acetonitrile was delivered
from Merck (Darmstadt, Germany) and formic acid from
POCh (Katowice, Poland). HPLC ELITE LaChrom VWR
(Merck) instrumentation consisted of the following compo-
nents: a pump series L-2130 in gradient mode, an autosam-
pler series L-2200 with a 100μL injection loop, Column
Oven series L-2350, and the diode array detector (DAD)
series L-2455. The chromatographic separation was per-
formed in the gradient mode with a Discovery RP 18 column
(250 × 4:6mm I.D., 5μm particle size) from Sigma-Aldrich
(Supelco).
The mobile stage consisted of the phase A which was
0.1% v/v formic acid (HCOOH) in water and the phase B
which was acetonitrile (0.050% TFA in acetonitrile/water
80 : 20 v/v). The flow rate increased from 0.6mL/min to
1.2mL/min for 11minutes and then decreased to 0.6mL/min.
The gradient was programmed as follows: 6% B for 11min,
then increased to 14% B for 3min, and then decreased to
6% B. Temperature of the column was equal to 15°C. The
applied gradient was linear from 0 to 55% in 11min, at a flow
rate of 1.2mL/min.
The DAD was set at a wavelength of 274nm. Mass spec-
tra were collected every 3ms in the positive ion mode. MS
spray voltage was 4.50 kV and the capillary temperature
was 250°C.
Table 1: Descriptive statistics for the examined group OLP patients, i.e., reticular and erosive forms, and controls dependent on gender.
P: normal distribution in all measurements, repeated measurement ANOVA test, and post hoc analysis results (Fisher’s LSD test for couples
associated); NP: no normality of distribution in at least one measurement, Kruskal-Wallis test, and post hoc results (Dunn’s test for associated
couples).
Parameter Males (N = 13) Females (N = 13) ∗p
Reticular OLP
GPx (mU/mL) Mean ± SD 379:51 ± 44:12 403:58 ± 50:7 0.209 P
Tyr (μmol/L) Mean ± SD 0:08 ± 0:02 0:08 ± 0:03 0.476 P
Uric acid (UA) (μmol/L) Mean ± SD 205:91 ± 4:47 207:42 ± 1:35 0.256 P
Erosive OLP
Parameter Males (N = 7) Females (N = 7) ∗p
GPx (mU/mL) Mean ± SD 388:64 ± 42:01 408:47 ± 39:06 0.378 P
Tyr (μmol/L) Mean ± SD 0:07 ± 0:02 0:07 ± 0:01 0.666 P
Uric acid (μmol/L)
Mean ± SD 193:37 ± 4:84 199:7 ± 5:55 0.064
Median 194.2 201.4 NP
Quartiles 190.75–195.05 200.35–202
OLP patients
Parameter Males (N = 20) Females (N = 20) ∗p
GPx (mU/mL) Mean ± SD 382:7 ± 42:51 405:3 ± 45:95 0.115 P
Tyr (μmol/L) Mean ± SD 0:07 ± 0:02 0:08 ± 0:02 0.655 P
UA (μmol/L)
Mean ± SD 201:52 ± 7:59 204:72 ± 5:01 0.267
Median 203.5 206.4 NP
Quartiles 195.32–208.43 202.25–207.72
Controls
Parameter Males (N = 20) Females (N = 20) ∗p
GPx (mU/mL) Mean ± SD 495:19 ± 30:28 501:19 ± 24:15 0.493 P
Tyr (μmol/L) Mean ± SD 0:13 ± 0:02 0:13 ± 0:02 0.854 P
UA (μmol/L)
Mean ± SD 218:18 ± 7:88 218:8 ± 4:83 0.323
Median 215.95 217.95 NP
Quartiles 212.4–220.72 215.52–221.25
All
Parameter Males (N = 40) Females (N = 40) ∗p
GPx (mU/mL)
Mean ± SD 438:94 ± 67:61 453:24 ± 60:58 0.368
Median 446.30 463.75 NP
Quartiles 380.75–495.45 421.48–498.68
Tyr (μmol/L) Mean ± SD 0:1 ± 0:04 0:1 ± 0:03 0.893 P
UA (μmol/L) Mean ± SD 209:85 ± 11:38 211:76 ± 8:63 0.4 P
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2.4. Determination of GPx. Determination of GPx in saliva
was performed using the method proposed by Paglia and
Valentine [24] with the modification of Lawrence and Burk
[25] using t-butylhydroperoxide as a substrate. GPx is a
catalyst for GSH oxidation. In the presence of glutathione
reductase (GR) and NADPH, the oxidized GSH (GSSG) is
converted to the reduced form (GSH) with concurrent
NADPH oxidation to NADP+.
H+ + GSSG + NADPH→ 2GSH +NADP+ ð1Þ
The GPx enzyme catalyzes the oxidation of GSH to a
form that reacts with NADPH and produces the oxidized
form of NADP and two reduced GSH molecules.
As much as 50μL of saliva was mixed with 1.5mL of
a reaction mixture containing 2mM β-NADPH, 1M
sodium azide, 100mM reduced GSH, and 100U/mL GR
(the GPx enzyme catalyzes the oxidation of GSH to a
form which reacts with NADPH and produces the oxidized
form of NADP and two GSH molecules). The reagents
were mixed by inversion, and 50μL of 5mM H2O2 was
added as an initiator of the reaction, while a decrease in
absorbance at λmax = 340 nm was measured. All measure-
ments were performed using the POLARstar plate reader
from BMG Labtech.
2.5. Determination of UA. The level of UA in saliva was
measured colorimetrically using a commercial enzyme
kit (cat. no. 1–3802, Salimetrics, CA, USA) according to
the manufacturer’s instructions. UA is converted by uri-
case into allantoin and hydrogen peroxide which oxidizes
4-aminophenazone to sodium N-ethylmethaniline propane-
sulfonate under the influence of peroxidase, producing a
red chromogen whose color intensity is proportional to the
amount of UA present in the saliva sample. The working
reagent (1mL) and saliva sample or blank standard
(0.020mL) were mixed and incubated for 5min at 37°C.
The absorbance values of the standard, test, and blank sam-
ples were read at a wavelength of λmax = 546 nm.
Table 2: Differences in the tested parameters (GPx, Tyr, and UA) in
the saliva of OLP patients and controls. P: normal distribution in all
measurements, repeated measurement Student’s t-test, and post hoc
analysis results (Fisher’s LSD test for associated couples); NP: no
normality of distribution in at least one measurement, Mann-
Whitney test, and post hoc results (Dunn’s test for couples
associated).
Parameter
OLP patients
(N = 40)
Controls
(N = 40)
∗p
GPx (mU/mL)
Mean ± SD 394 ± 45:16 498:19 ± 27:2 <0.001
Median 390.25 497.40 NP
Quartiles 363.93–433.25 478.5–516.2
Tyr (μmol/L)
Mean ± SD 0:08 ± 0:02 0:13 ± 0:02 <0.001 P
UA (μmol/L)
Mean ± SD 203:12 ± 6:55 218:49 ± 6:46 <0.001
Median 204.9 217.4 NP
Quartiles 201.15–208.4 214.25–220.72
∗P—Student’s t-test (normal distribution in groups); NP—Mann-Whitney
test (nonnormal distribution in at least one group).
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Figure 2: Violin plot representing tyrosine (Tyr), uric acid (UA),
and glutathione peroxidase (GPx) activity in the group of OLP
patients and controls. The dots on the graph represent individual
results in each group.
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2.6. Statistical Evaluation. The calculation of the results was
based on the regression equation for the 10 series of standard
curves in μmol/mL. Thus, the obtained results were com-
pared with the results obtained using an external standard
(L-Trp and D-Tyr). Comparisons of quantitative variables
in two groups were done with Student’s t-test (in case of nor-
mal distribution in both groups) or with the Mann-Whitney
test (otherwise). Comparisons of quantitative variables in
more than two groups were performed using ANOVA
(in case of normal distribution in each group) or with
Kruskal-Wallis test (otherwise). Fisher’s LSD test (in case of
normal distribution in each group) or Dunn’s test (other-
wise) was used as post hoc procedure. Correlations between
quantitative variables were assessed with Pearson’s test
(in case of normal distribution of both variables) or
Spearman’s test (otherwise) correlation coefficient. The
strength of association was judged with Hinkle’s scheme:
∣r∣ ≥ 0:9—very strong, 0:7 ≤ ∣r∣ < 0:9—strong, 0:5 ≤ ∣r∣ < 0:7
—moderate, 0:3 ≤ ∣r∣ < 0:5—weak, and ∣r∣ < 0:3—very weak
[26]. Normality was assessed with the Shapiro-Wilk test.
Analyses were conducted at 0.05 level of significance. For
all statistical analyses, the R software, version 3.6.1, was used.
3. Results
Basic descriptive statistics for Tyr concentration (μmol/mL),
GPx activity (mU/mL), and UA concentration (μmol/L) in
saliva of the study participants are presented in Table 1.
Due to the fact that there were no statistically significant
differences in terms of gender for the studied parameters
(p > 0:05; Table 1), subsequent analyses were performed
without division into groups of females and males.
For each of the tested parameters, i.e., Tyr, GPx, and UA,
the differences between the group of patients with OLP and
the control group were statistically significant, as presented
in Table 2. All tested parameters were higher in the control
group than in patients with OLP. These differences are illus-
trated in Figure 2.
For each of the tested parameters, the differences between
the groups were significant (Table 2, Figure 2). A post hoc
analysis was performed to assess the nature of dependen-
cies. Levels of GPx and Tyr were significantly higher in
the control group than in both groups of patients with
OLP which did not differ from each other. Concentration
of UA, however, was significantly higher in the control
group than in the reticular group, which, in turn, was sig-
nificantly higher than in the erosive group as presented in
Table 3 and Figure 3.
All three parameters correlate significantly and positively
(p < 0:05); the higher the value of one of them, the higher the
values of the remaining ones as illustrated in Table 4 and
Figure 4.
The results of Tyr concentration obtained using the
HPLC method correlated significantly (strong positive corre-
lation) with the results of GPx activity and UA concentra-
tions in saliva (Figure 5).
4. Discussion
4.1. Glutathione Peroxidase (GPx). It is increasingly common
practice that the research into new biomarkers of oral dis-
eases, including OLP, is focused on the determination of dis-
ease predictors in a noninvasively derived material, such as
saliva, due to the ease of collection and the fact that it repre-
sents a good alternative to the invasive method, i.e., tissue
biopsy [27]. Collection of saliva is a simple procedure which
can be carried out as often as necessary, without any compli-
cations, such as pain sensations, that may follow invasive
testing such as blood or tissue collection. The documented
correlation between the aforementioned parameters in the
saliva, blood, or tissues determines the use of saliva as a bio-
logical fluid reflecting the intensification and rate of patho-
logical changes with local nature (notably in the case of oral
Table 3: Comparison of the glutathione peroxidase (GPx) activity and tyrosine and uric acid (UA) concentrations within groups, i.e., patients
with the reticular form, patients with the erosive form, and healthy individuals without symptoms of the disease: A, B, and C. Statistically
significant differences between particular groups are recorded in column 4; p means statistical significance at <0.05; differences between
particular groups: A-C were examined by Fisher’s post hoc test when the assumptions about normality and homogeneity of variance in
groups were true or Dunn’s test if otherwise.
Parameter Reticular OLP (A) (N = 26) Erosive OLP (B) (N = 14) Controls (C) (N = 40) ∗p
GPx (mU/mL)
Mean ± SD 391:55 ± 48:16 398:56 ± 40:31 498:19 ± 27:2
<0.001
P
C > A, B
Tyr (μmol/L)
Mean ± SD 0:08 ± 0:03 0:07 ± 0:02 0:13 ± 0:02
<0.001
P
C > A, B
Uric acid (μmol/L)
Mean ± SD 206:66 ± 3:33 196:54 ± 5:98 218:49 ± 6:46 <0.001
Median 206.95 197.95 217.40 NP
Quartiles 205.22–208.5 192.62–201.47 214.25–220.72 C > A > B
∗P—ANOVA+Fisher LSD test (normal distribution in groups); NP—Kruskal-Wallis test+Dunn test (nonnormal distribution in at least one group).
6 Oxidative Medicine and Cellular Longevity
cavity diseases) [14, 28]. Thus, this study focused on the
determination of the levels of selected antioxidants (the enzy-
matic antioxidant glutathione peroxidase (GPx) and the non-
enzymatic antioxidant with its major representative uric acid
(UA)) in the saliva of patients with OLP.
The present study also investigated the levels of tyrosine,
one of the most important AAA in the human body regulat-
ing the cellular metabolism necessary for the synthesis of
endogenous proteins. Specifically, we verified the hypothesis
that alterations in concentrations of the above parameters in
saliva may reflect the capacity of the human body to prevent
the effects caused by reactive oxygen and nitrogen species
(ROS/RNS) generating oxidative/nitrosative stress associated
with the pathogenesis of OLP [29].
In the study by Rekha et al. [30], the activity of GPx deter-
mined for 40 patients with OLP, the levels of salivary GPx
(0:06 ± 0:03) in patients with OLP were significantly lower
than in controls, which is in line with our results. Likewise,
in the study by Totan et al. [14], GPx activity was similar to
that in our study. The mean GPx value in the saliva of
patients was significantly lower than that of controls
(28:16 ± 11:95 U/mg albumins vs. 29:97 ± 17:78 U/mg albu-
mins, respectively). In the current study, a similar decrease in
GPx activity was observed in OLP as compared with controls,
although a comparison of absolute GPx activity values was
impossible due to the material used for testing (higher values
in the serum than in plasma) and the different method and
period of material storage. In none of the cited studies was
there an addition of butylated hydroxytoluene (BHT) to limit
in vitro lipid or protein peroxidation. Furthermore, Rekha
et al. [30] provided neither the units in which the results were
calculated nor the literature references for the measurement
method, despite the fact that the authors used the spectro-
photometric method and sample to reagent ratios similar to
ours [30].
The statistical analyses performed in this study further
demonstrated an upward trend in mean GPx activities in
patients with the reticular form in comparison to the erosive
oral lichen planus form in relation to the control group. The
GPx values were lower in those patients with the reticular as
opposed to the erosive form and lower in OLP than in con-
trols without significant differences within sexes.
The observed changes can be explained by the higher
compensation of GPx in patients with the erosive form
as compared with the reticular form, following the
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Figure 3: Violin plot representing tyrosine (Tyr), uric acid (UA),
and glutathione peroxidase (GPx) activity in the subgroups of
patients (erosive and reticular OLP) and controls. The dots on the
graph represent individual results in each group.
Table 4: Relationship between the tested antioxidant parameters,
i.e., GPx and uric acid (UA), GPx and Tyr, and between UA and
Tyr. Significance level ∗p < 0:001; correlation coefficient r; a
positive correlation direction means that the increase in GPx
activity is accompanied by an increase in results of Tyr or UA.
The higher the GPx activity on one variable (e.g., x axis), the
higher the UA result on the other variable (y axis). The strength of
the relationship between the tested parameters is high.
Parameters
Correlation
Coefficient (r) ∗p Direction Strength
GPx and Tyr 0.824 p < 0:001 NP Positive Strong
GPx and UA 0.826 p < 0:001 NP Positive Strong
Tyr and UA 0.792 p < 0:001 P Positive Strong
∗P—Pearson correlation (normal for both parameters); NP—Spearman rank
correlation (nonnormal distribution of at least one parameter).
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chemopreventive action of the enzyme in the course of more
intense oxidative changes. This can also be explained by the
fact that the higher activity of GPx in its erosive form may
suggest a reduced likelihood for the attack of oxygen free rad-
icals in the site of enzyme action. The obtained results are in
accordance with those of other studies in terms of the drop in
GPx activity in OLP (without the clinical differential of the
disease phenotype). Considering the fact that no published
results from studies exist, which would differentiate between
GPx activity based on the clinical form of OLP, a more
detailed comparison of the obtained results (particularly of
the absolute values of GPx) is not possible.
4.2. Uric Acid (UA). Statistically significant differences
between patients with OLP and the control group were
observed in terms of the level of the salivary nonenzymatic
antioxidant, that is, uric acid (UA). Uric acid being the most
abundant antioxidative compound in saliva is one of the
most sensitive biomarkers used to detect oxidative-
antioxidative changes in the course of various diseases. Its
role consists of the efficient removal of free oxygen radicals
and inhibition of lipid peroxidation [31]. The present study
considered only the salivary level of UA due to the linear
relationship between the concentrations of UA in saliva
and serum as previously reported [32]. In our study, UA
was lower in the group of OLP patients than in the con-
trols. A similar decreasing trend was observed by Totan
et al. who found that the salivary level of UA in OLP
patients was significantly lower than that in controls
[14]. Results similar to ours were demonstrated by Battino
et al. [33] and Miricescu et al. who noted a significant
decrease in the salivary concentration of UA in comparison
with healthy individuals (1.5–2mg/dL in OLP vs. 3mg/dL
in controls) [34]. On the other hand, Gupta et al. found a
marked reduction of UA levels in the serum of OLP patients
in comparison with controls (4:058 ± 1:31 vs. 5:28 ± 0:961
mg/dL) [35]. By contrast, an increased level of salivary UA
has been observed in the majority of generalized pathologic
conditions such as diabetes and cardiovascular disorders,
which might explain the systemic oxidative stress [36–38],
as opposed to changes of local nature. The increase in UA
levels in these studies may constitute a compensatory antiox-
idative defense system of the entire human body aimed at
preventing generalized oxidative stress.
Methodological differences (namely, stimulated vs. non-
stimulated saliva collection method) as well as demographic
differences between the examined patients hinder the ade-
quate comparison of the obtained uric acid concentrations.
Furthermore, the present study revealed significant differ-
ences in terms of the UA level between reticulate and erosive
forms of OLP. However, unlike GPx, the UA concentrations
were significantly lower in the erosive form of OLP in com-
parison with its reticulate counterpart and controls. Similar
observations were made by Gupta et al. [35], who observed
that the UA level correlates with an exacerbation of OLP as
compared with healthy controls. Similarly, OLP patients in
remission exhibited lower UA levels than individuals with
an exacerbation of the disease symptoms [35]. Some studies
have also indicated a lack of differences between mean UA
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Figure 4: Scatter (correlation) charts depicting the relationships
between the studied parameters, i.e., tyrosine, glutathione
peroxidase, and uric acid. Individual observations are shown in
groups.
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concentrations in patients with diabetes with different blood
glucose levels, which suggests the possibility of similarities
between UA concentrations in patients based on their gly-
cated hemoglobin profiles [39, 40].
4.3. Tyrosine (Tyr). Among recognized parameters used for
the assessment of oxidative and antioxidative status in OLP,
we tested the salivary level of Tyr. It is believed to participate
in the molecular mechanism (by PI3K/Akt signaling stimula-
tion and by NF-κB and p53 transcription factor activation)
constituting the basis for malignant degeneration [20].
Hence, we attempted to test the hypothesis that there are
differences in its level in distinct clinical phenotype of
OLP. In the case of patients with erosive oral lichen pla-
nus, a lower Tyr level was observed in comparison with
patients with the reticulate form but not statistically signif-
icant. We suspect that this may constitute a negative sign
indicating a gradual blockage of the antioxidative defense
and a poorer response of the patients to the ongoing
oxidative/nitrosative stress.
Our hypothesis may be supported by Chaiyarit et al., who
showed a link between one of the Tyr modifications, i.e.,
3-nitrotyrosine, and immunoreactivity; this is believed to be
a biochemical marker of inflammation, particularly observed
in the squamous cell cancer (OSCC) which is the one possible
course of the oral lichen planus [41]. Our study was the first,
so comparison of these results with other studies is impossi-
ble. It has been demonstrated that the formation of Tyr mod-
ifications may disturb the structure and physiological
function of numerous proteins, intensifying oxidative stress
up to the loss of their function. Detection of the presence of
Tyr and its modifications in the saliva may be a promising
marker differentiating the clinical disease phenotype in
the future.
The present study is the first to verify in vivo the hypoth-
esis of the lack of redox homeostasis due to the presence of
different Tyr levels, which—together with Tyr modifica-
tions—may influence cellular homeostasis and redox signal-
ing pathways under clinical conditions in OLP patients. In
addition, our further and unpublished results determined
which of the formed Tyr modifications (i.e., 3-hydroxy-
tyrosine, tyrosine crossbonds, 3-nitrotyrosine, or halogenated
tyrosine) have an impact on cellular functions, such as
changes in the extracellular matrix or apoptosis of epithelial
cells, which may be the cause for progression of the formed
changes, including malignant degeneration in this group of
patients. In the future, this would aid in the formulation of
algorithms for procedures in patients for whom untreated
erosive OLP could undergo malignant transformation.
Provision of information on the precisely modified Tyr
residuals and the character of these modifications could help
to understand the consequences for oxidation Tyr in clinical
conditions, including determination of their influence on the
cellular signaling and dysfunction of cells in different clinical
forms of OLP.
It should be noted that the etiology of OLP is still
unknown, despite the high incidence of the disease. OSCC
is often preceded by potentially malignant disorders, such
as leukoplakia, oral submucosal fibrosis, or OLP (particularly
its rapidly advancing erosive form). Oxidative and nitrosative
stresses play a significant role in the pathogenesis of OLP, as
well as in the progression of its distinct clinical forms. There-
fore, noninvasive monitoring of potential biomarkers of
disease and their correlation with the clinical phenotype of
the disease could play a key role in the early detection of
malignancy. The available literature in this field is scarce.
The preliminary conclusion from our study is that tyrosine,
alongside UA and GPx, can also constitute a promising bio-
marker of the oral lichen planus patients based on saliva tests.
It may be a promising marker for the assessment of
oxidative-antioxidative balance and monitoring of the clini-
cal status of OLP patients.
The limitation of the present study is the small sizes of the
studied groups with clinical OLP subtypes and the high level
of age diversity in the study groups. Furthermore, only Tyr
levels were determined, without its nitrosative modifications.
5. Conclusions
The results of the present study suggest that, apart from the
salivary antioxidants such as UA and GPx, tyrosine should
also be taken into account as a useful biomarker providing
information on the oxidative-antioxidative balance in OLP.
In addition, the study provides evidence for the use of the
above parameters in the monitoring of clinical forms of oral
lichen planus, such as the reticulate and erosive forms. There
is a need for further research to confirm the presented results.
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Figure 5: Sample chromatogram (HPLC) for tyrosine and its derivatives: (a) calibration curve and (b) examined sample.
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